Following the lead from overseas the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) is flying higher today. It has so far climbed an impressive 1.8% to 5,391 points.

Despite the strong gains today, some shares have been defying the market trend and heading lower. Here are four shares heading lower today:

Newcrest Mining Limited (ASX: NCM) shares have declined by around 4.5% to $19.15 following a drop in gold futures to US$1,228 per troy ounce. With Citigroup predicting that the price of gold could drop to US$1,000, further declines could potentially be on the way for shareholders of this gold miner.

Despite recent declines, Newcrest Mining’s share price is still up by 47% in 2016.

Saracen Mineral Holdings Limited (ASX: SAR) shareholders will be disappointed to see its share price drop by around 9% today to $1.16. Although it is classed as a mineral exploration and development company, its focus is primarily on gold. So just like Newcrest Mining and Resolute Mining Limited (ASX: RSG), it is likely to see its share price drop if the gold price continues to decline.

Saracen Minerals has been on a tear this year with an 88% return for shareholders.

Shine Corporate Ltd (ASX: SHJ) shares have dropped around 4% to $1.22 today despite no news being released to market. With the share price of the embattled law firm up by around 80% in the last three months, today’s decline could be attributed to profit taking. I believe both Shine Corporate and Slater & Gordon Limited (ASX: SGH) are liable to wild swings in their share prices at the moment, which make them high-risk investments.

Despite the strong gains in the last three months, Shine Corporate’s share price is still down 38% this year.

Sirtex Medical Limited (ASX: SRX) has seen its share price sink 2.5% to $30.10. Shareholders of this cancer treatment company have suffered a disappointing 2016, but if it can deliver on its earnings expectations I believe the share price could retrace a lot of its declines. According to CommSec, analysts are expecting earnings to grow by a massive 45% per annum for the next couple of years. This could make the latest drop an opportunity to buy in at a good price, in my opinion.

Sirtex shares are now down by 25% so far in 2016.

If you've suffered declines today then I believe adding one of these three blue chip shares to your portfolio could be a great way of getting it going again. I expect all of them to produce strong returns for shareholders in the year ahead.

Why These 3 Blue Chip Shares Look Set to Soar in 2016

Discover The Motley Fool's top 3 blue chips for 2016. These 3 'new breed' shares pay fully franked dividends AND offer the very real prospect of significant capital appreciation. Simply click here to gain access to this comprehensive FREE investment report.

No credit card required.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.